Research Report
Impulsivity predicts poorer improvement in quality of life during early treatment for people with methamphetamine dependence
Adam J. Rubenis,
Rebecca E. Fitzpatrick,
Dan I. Lubman,
Antonio Verdejo-Garcia,
Adam J. Rubenis
Monash Institute of Cognitive and Clinical Neurosciences, Monash University, Clayton, VIC, Australia
Search for more papers by this authorRebecca E. Fitzpatrick
Monash Institute of Cognitive and Clinical Neurosciences, Monash University, Clayton, VIC, Australia
Search for more papers by this authorDan I. Lubman
Turning Point, Eastern Health, Fitzroy, VIC, Australia
Eastern Health Clinical School, Monash University, Fitzroy, VIC, Australia
Search for more papers by this authorCorresponding Author
Antonio Verdejo-Garcia
Monash Institute of Cognitive and Clinical Neurosciences, Monash University, Clayton, VIC, Australia
Correspondence to: Antonio Verdejo-Garcia, Monash Institute of Cognitive and Clinical Neurosciences, Monash University, 18 Innovation Walk, Clayton, VIC 3800, Australia. E-mail: [email protected]Search for more papers by this authorAdam J. Rubenis,
Rebecca E. Fitzpatrick,
Dan I. Lubman,
Antonio Verdejo-Garcia,
Adam J. Rubenis
Monash Institute of Cognitive and Clinical Neurosciences, Monash University, Clayton, VIC, Australia
Search for more papers by this authorRebecca E. Fitzpatrick
Monash Institute of Cognitive and Clinical Neurosciences, Monash University, Clayton, VIC, Australia
Search for more papers by this authorDan I. Lubman
Turning Point, Eastern Health, Fitzroy, VIC, Australia
Eastern Health Clinical School, Monash University, Fitzroy, VIC, Australia
Search for more papers by this authorCorresponding Author
Antonio Verdejo-Garcia
Monash Institute of Cognitive and Clinical Neurosciences, Monash University, Clayton, VIC, Australia
Correspondence to: Antonio Verdejo-Garcia, Monash Institute of Cognitive and Clinical Neurosciences, Monash University, 18 Innovation Walk, Clayton, VIC 3800, Australia. E-mail: [email protected]Search for more papers by this authorAbstract
Background and aims
Methamphetamine dependence is associated with heightened impulsivity and diminished quality of life, but the link between impulsivity and changes in quality of life during treatment has not been examined. We aimed to investigate how different elements of impulsivity predict change in quality of life in the 6 weeks after engaging in treatment.
Design
Longitudinal, observational cohort study.
Setting
Public and private detoxification and rehabilitation facilities in metropolitan Melbourne, Australia.
Participants
One hundred and eight individuals with methamphetamine dependence (81 male) tested within 3 weeks of commencing treatment; 80 (74%) were followed-up at 6 weeks.
Measurements
The Continuous Performance Test-2 measured impulsive action (cognitive and motor impulsivity); the Delay Discounting Task measured impulsive choice. Quality of life was measured with the World Health Organization Quality of Life Scale—Brief, which includes social, psychological, physical and environment domains. Control variables included age, gender, estimated IQ, depression severity score, methamphetamine dependence severity score, cannabis dependence severity score and treatment modality.
Findings
We found that all three forms of impulsivity were significant predictors of change in the social domain: motor impulsivity (β = −0.54, P = 0.013), cognitive impulsivity (β = −0.46, P = 0.029) and impulsive choice (β = −0.26, P = 0.019). Change in the psychological domain was predicted significantly by motor impulsivity (β = −0.45, P = 0.046). Control variables of age and depression were associated significantly with changes in the physical domain.
Conclusions
In Australian methamphetamine-dependent individuals, elevated impulsivity predicts lower improvement of social and psychological quality of life in the first 6–9 weeks of treatment.
References
- 1Luan X., Ren W., Zhao K., Su H., Shen H., Chen H., et al. High prevalence of depressive symptoms and impulsivity as well as their relationship during subacute methamphetamine withdrawal in chronic abusers. J Clin Neurosci 2017; 39: 1–3.
- 2McKetin R., Lubman D. I., Najman J. M., Dawe S., Butterworth P., Baker A. L. Does methamphetamine use increase violent behaviour? Evidence from a prospective longitudinal study. Addiction 2014; 109: 798–806.
- 3Gonzales R., Ang A., Glik D. C., Rawson R. A., Lee S., Iguchi M. Y. Quality of life among treatment seeking methamphetamine-dependent individuals. Am J Addict 2011; 20: 366–372.
- 4 WHO QOL Group Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychol Med 1998; 28: 551–558.
- 5Ellis C., Hoffman W., Jaehnert S., Plagge J., Loftis J. M., Schwartz D. et al. Everyday problems with executive dysfunction and impulsivity in adults recovering from methamphetamine addiction. Addict Disord Their Treat 2016; 15: 1–5.
- 6Rusyniak D. E. Neurologic manifestations of chronic methamphetamine abuse. Psychiatr Clin North Am 2013; 36: 261–275.
- 7Maxwell J. C. A new survey of methamphetamine users in treatment: who they are, why they like ‘Meth’, and why they need additional services. Subst Use Misuse 2014; 49: 639–644.
- 8Laudet A. B., Becker J. B., White W. L. Don't wanna go through that madness no more: quality of life satisfaction as predictor of sustained remission from illicit drug misuse. Subst Use Misuse 2009; 44: 227–252.
- 9Tiffany S. T., Friedman L., Greenfield S. F., Hasin D. S., Jackson R. Beyond drug use: a systematic consideration of other outcomes in evaluations of treatments for substance use disorders. Addiction 2012; 107: 709–718.
- 10Henry B. L., Minassian A., Perry W. Effect of methamphetamine dependence on everyday functional ability. Addict Behav 2010; 35: 593–598.
- 11Mahoney J. J., Thompson-Lake D. G. Y., Cooper K., Verrico C. D., Newton T. F., De La Garza R. A comparison of impulsivity, depressive symptoms, lifetime stress and sensation seeking in healthy controls versus participants with cocaine or methamphetamine use disorders. J Psychopharmacol 2015; 29: 50–56.
- 12Albein-Urios N., Pilatti A., Lozano Ó., Martínez-González J. M., Verdejo-García A. The value of impulsivity to define subgroups of addicted individuals differing in personality dysfunction, craving, psychosocial adjustment, and wellbeing: a latent class analysis. Arch Clin Neuropsychol 2014; 29: 38–46.
- 13Stevens L., Verdejo-Garcia A., Goudriaan A. E., Roeyers H., Dom G., Vanderplasschen W. Impulsivity as a vulnerability factor for poor addiction treatment outcomes: a review. J Subst Abuse Treat 2014; 47: 58–72.
- 14Frijda N. H., Ridderinkhof K. R., Rietveld E. Impulsive action: emotional impulses and their control. Front Psychol 2014; 5: 1–9.
- 15Malloy-Diniz L., Fuentes D., Leite W. B., Correa H., Bechara A. Impulsive behavior in adults with attention deficit/hyperactivity disorder: characterization of attentional, motor and cognitive impulsiveness. J Int Neuropsychol Soc 2007; 13: 693–698.
- 16Perry J. L., Carroll M. E. The role of impulsive behavior in drug abuse. Psychopharmacology (Berl) 2008; 200: 1–26.
- 17Morgan E. E., Doyle K. L., Minassian A., Henry B. L., Perry W., Marcotte T. D. et al. Elevated intraindividual variability in methamphetamine dependence is associated with poorer everyday functioning. Psychiatry Res 2014; 220: 527–534.
- 18Cattie J. E., Woods S. P., Iudicello J. E., Posada C., Grant I. Elevated neurobehavioral symptoms are associated with everyday functioning problems in chronic methamphetamine users. J Neuropsychiatry Clin Neurosci 2012; 24: 331–339.
- 19Brecht M., Herbeck D. Time to relapse following treatment for methamphetamine use: a long-term perspective on patterns and predictors. Drug Alcohol Depend 2014; 139: 18–25.
- 20Bagheri M., Mokri A., Khosravi A., Kabir K. Effect of abstinence on depression, anxiety, and quality of life in chronic methamphetamine users in a therapeutic community. Int J High Risk Behav Addict 2015; 4; e23903.
- 21Simon S. L., Dean A. C., Cordova X., Monterosso J. R., London E. D. Methamphetamine dependence and neuropsychological functioning: evaluating change during early abstinence. J Stud Alcohol Drugs 2010; 71: 335–344.
- 22First M. B., Spitzer R. L., Gibbon M., Williams J. B. W. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). Washington, DC: American Psychiatric Press, Inc.; 1996.
- 23Gossop M., Darke S., Griffiths P., Hando J., Powis B., Hall W. et al. The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction 1995; 90: 607–614.
- 24Gossop M., Best D., Marsden J., Strang J. Test–retest reliability of the severity of dependence scale. Addiction 1997; 92: 353–354.
- 25Wechsler D., Hsiao-pin C. WASI-II: Wechsler Abbreviated Scale of Intelligence. San Antonio, TX: Pearson; 2011.
- 26Cuzen N. L., Koopowitz S.-M., Ferrett H. L., Stein D. J., Yurgelun-Todd D. Methamphetamine and cannabis abuse in adolescence: a quasi-experimental study on specific and long-term neurocognitive effects. BMJ Open 2015; 5: e005833.
- 27Golub E. T., Latka M., Hagan H., Havens J. R., Hudson S. M., Kapadia F. et al. Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the Beck Depression Inventory. J Urban Health 2004; 81: 278–290.
- 28Orme J. G., Reis J., Herz E. J. Factorial and discriminant validity of the center for epidemiological studies depression (CES-D) scale. J Clin Psychol 1986; 42: 28–33.
10.1002/1097-4679(198601)42:1<28::AID-JCLP2270420104>3.0.CO;2-T CAS PubMed Web of Science® Google Scholar
- 29Conners B. C. K. Conners’ Continuous Performance Test II (CPT II): version 5 for Windows: Technical Guide and Software Manual. North Tonawanda, NY: Multi-Health Systems Inc.; 2004.
- 30Hosak L., Preiss M., Bazant J., Tibenska A., Holub D., Cermakova R. et al. Comparison of continuous performance test results between subjects dependent on methamphetamine and healthy volunteers. Act Nerv Super Rediviva 2011; 53: 182–186.
- 31Kirby K. N., Maraković N. N. Delay-discounting probabilistic rewards: rates decrease as amounts increase. Psychon Bull Rev 1996; 3: 100–104.
- 32Kirby K. N., Petry N. M., Bickel W. K. Heroin addicts have higher discount rates for delayed rewards than non-drug-using controls. J Exp Psychol Gen 1999; 128: 78–87.
- 33Murphy B., Herman H., Hawthorne G., Pinzone T., Evert H. Australian WHO QOL Instruments: User's Manual and Interpretation Guide. Melbourne, Australia: Australian WHO QOL Field Study Centre; 2000.
- 34Skevington S. M., Lotfy M., O'Connell K. A. The World Health Organization's WHO QOL-BREF quality of life assessment: psychometric properties and results of the international field trial. Qual Life Res 2004; 13: 299–310.
- 35Barros da Silva Lima A. F., Fleck M., Pechansky F., De Boni R., Sukop P. Psychometric properties of the World Health Organization quality of life instrument (WHO QOL-BREF) in alcoholic males: a pilot study. Qual Life Res 2005; 14: 473–478.
- 36Tabachnick B. G., Fidell L. S. Using Multivariate Statistics, 6th edn. Boston, MA: Pearson International Ed; 2013.
- 37Enders C. K. Applied Missing Data Analysis. New York, NY: Guilford Press; 2010.
- 38Henry J. D., Mazur M., Rendell P. G. Social-cognitive difficulties in former users of methamphetamine. Br J Clin Psychol 2009; 48: 323–327.
- 39Homer B. D., Solomon T. M., Moeller R. W., Mascia A., DeRaleau L., Halkitis P. N. Methamphetamine abuse and impairment of social functioning: a review of the underlying neurophysiological causes and behavioral implications. Psychol Bull 2008; 134: 301–310.
- 40Best D., Beckwith M., Haslam C., Haslam S. A., Jetten J., Mawson E., et al. Overcoming alcohol and other drug addiction as a process of social identity transition: the social identity model of recovery (SIMOR). Addict Res Theory 2016; 24: 111–123.
- 41Cloud W., Granfield R. Conceptualizing recovery capital: expansion of a theoretical construct. Subst Use Misuse 2008; 43: 1971–1986.
- 42Boeri M., Gibson D., Boshears P. Conceptualizing social recovery: recovery routes of methamphetamine users. J Qual Crim Justice Criminol 2014; 2: 5–38.
- 43Gregg L., Haddock G., Emsley R., Barrowclough C. Reasons for substance use and their relationship to subclinical psychotic and affective symptoms, coping, and substance use in a nonclinical sample. Psychol Addict Behav 2014; 28: 247–256.
- 44Casaletto K. B., Obermeit L., Morgan E. E., Weber E., Franklin D. R., Grant I. et al. Addictive Behaviors Depression and executive dysfunction contribute to a metamemory deficit among individuals with methamphetamine use disorders. Addict Behav 2015; 40: 45–50.
- 45Smith G. T., Cyders M. A. Integrating affect and impulsivity: the role of positive and negative urgency in substance use risk. Drug Alcohol Depend 2016; 163: S3–S12.
- 46Hartwell E. E., Ray L. Differences in clinical presentation between high and low impulsive methamphetamine users. Drug Alcohol Depend 2017; 171: e83.
- 47McGregor C., Srisurapanont M., Jittiwutikarn J., Laobhripatr S., Wongtan T., White J. M. The nature, time course and severity of methamphetamine withdrawal. Addiction 2005; 100: 1320–1329.
- 48Laudet A. B. The case for considering quality of life in addiction research and clinical practice. Addict Sci Clin Pract 2011; 6: 44–55.
- 49Lubman D. I., Garfield J. B. B., Manning V., Berends L., Best D., Mugavin J. M. et al. Characteristics of individuals presenting to treatment for primary alcohol problems versus other drug problems in the Australian patient pathways study. BMC Psychiatry 2016; 16: 250.
- 50Donovan D. M., Bigelow G. E., Brigham G. S., Carroll K. M., Cohen A. J., Gardin J. G. et al. Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use end-points in clinical trials. Addiction 2012; 107: 694–708.
- 51McKetin R., Najman J. M., Baker A. L., Lubman D. I., Dawe S., Ali R. et al. Evaluating the impact of community-based treatment options on methamphetamine use: findings from the Methamphetamine Treatment Evaluation Study (MATES). Addiction 2012; 107: 1998–2008.
- 52Casaletto K. B., Moore D. J., Woods S. P., Umlauf A., Scott J. C., Heaton R. Abbreviated Goal Management Training shows preliminary evidence as a neurorehabilitation tool for HIV-associated neurocognitive disorders among substance users. Clin Neuropsychol 2016; 30: 107–130.
- 53Valls-Serrano C., Caracuel A., Verdejo-Garcia A. Goal management training and mindfulness meditation improves executive functions and transfers to ecological tasks of daily life in polysubstance users enrolled in therapeutic community treatment. Drug Alcohol Depend 2016; 165: 9–14.
- 54Tomko R. L., Bountress K. E., Gray K. M. Personalizing substance use treatment based on pre-treatment impulsivity and sensation seeking: a review. Drug Alcohol Depend 2016; 167: 1–7.
